Search Results - "Guerrero, Lisa J."

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone by Chlenski, Alexandre, Guerrero, Lisa J, Salwen, Helen R, Yang, Qiwei, Tian, Yufeng, Morales La Madrid, Andres, Mirzoeva, Salida, Bouyer, Patrice G, Xu, David, Walker, Matthew, Cohn, Susan L

    Published in PloS one (16-09-2011)
    “…Secreted Protein Acidic and Rich in Cysteine (SPARC) is one of the major non-structural proteins of the extracellular matrix (ECM) in remodeling tissues. The…”
    Get full text
    Journal Article
  2. 2

    Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors by Chlenski, Alexandre, Guerrero, Lisa J, Peddinti, Radhika, Spitz, Jared A, Leonhardt, Payton T, Yang, Qiwei, Tian, Yufeng, Salwen, Helen R, Cohn, Susan L

    Published in Molecular cancer (04-06-2010)
    “…New, more effective strategies are needed to treat highly aggressive neuroblastoma. Our laboratory has previously shown that full-length Secreted Protein…”
    Get full text
    Journal Article
  3. 3

    Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines by Yang, Qiwei, Tian, Yufeng, Ostler, Kelly R, Chlenski, Alexandre, Guerrero, Lisa J, Salwen, Helen R, Godley, Lucy A, Cohn, Susan L

    Published in BMC cancer (14-06-2010)
    “…Epigenetic aberrations and a CpG island methylator phenotype have been shown to be associated with poor outcomes in children with neuroblastoma (NB). Seven…”
    Get full text
    Journal Article
  4. 4

    Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids by Chlenski, Alexandre, Dobratic, Marija, Salwen, Helen R, Applebaum, Mark, Guerrero, Lisa J, Miller, Ryan, DeWane, Gillian, Solomaha, Elena, Marks, Jeremy D, Cohn, Susan L

    Published in Oncotarget (22-11-2016)
    “…SPARC is a matrix protein that mediates interactions between cells and the microenvironment. In cancer, SPARC may either promote or inhibit tumor growth…”
    Get full text
    Journal Article
  5. 5

    SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix by Chlenski, Alexandre, Liu, Shuqing, Guerrero, Lisa J., Yang, Qiwei, Tian, Yufeng, Salwen, Helen R., Zage, Peter, Cohn, Susan L.

    Published in International journal of cancer (15-01-2006)
    “…Secreted protein, acidic and rich in cysteine (SPARC), is a multifunctional matricellular glycoprotein. In vitro, SPARC has antiangiogenic properties,…”
    Get full text
    Journal Article
  6. 6

    Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth by Kakodkar, Nisha C., Peddinti, Radhika R., Tian, Yufeng, Guerrero, Lisa J., Chlenski, Alexandre, Yang, Qiwei, Salwen, Helen R., Maitland, Michael L., Cohn, Susan L.

    Published in Pediatric blood & cancer (01-10-2012)
    “…Background More effective therapy for children with high‐risk neuroblastoma is desperately needed. Preclinical studies have shown that neuroblastoma tumor…”
    Get full text
    Journal Article
  7. 7

    The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth by Kakodkar, Nisha C., Peddinti, Radhika, Kletzel, Morris, Tian, Yufeng, Guerrero, Lisa J., Undevia, Samir D., Geary, David, Chlenski, Alexandre, Yang, Qiwei, Salwen, Helen R., Cohn, Susan L.

    Published in Pediatric blood & cancer (01-01-2011)
    “…The quinoxaline anti‐tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14‐year old with relapsed…”
    Get full text
    Journal Article
  8. 8

    The Quinoxaline Antitumor Agent (R+)XK469 Inhibits Neuroblastoma Tumor Growth by Kakodkar, Nisha C., Peddinti, Radhika, Kletzel, Morris, Tian, Yufeng, Guerrero, Lisa J., Undevia, Samir D., Geary, David, Chlenski, Alexandre, Yang, Qiwei, Salwen, Helen R., Cohn, Susan L.

    Published in Pediatric blood & cancer (01-01-2011)
    “…The quinoxaline antitumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14 year-old with relapsed neuroblastoma…”
    Get full text
    Journal Article